Form 4: Neumora Director David Piacquad Receives Stock Options
Statement of Changes in Beneficial Ownership
Neumora Therapeutics director David Piacquad was granted 80,000 stock options as part of standard equity compensation.
Summary
- Director David Piacquad was granted 80,000 stock options to purchase common stock.
- The options have an exercise price of $1.86 per share.
- The grant date for the options is May 27, 2026.
- The options are set to expire on May 26, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation that carries no significant signal regarding company performance or strategic direction.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the underlying common stock relative to the $1.86 exercise price.
Future Outlook
The options vest on the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting, indicating a standard short-term vesting schedule for director equity.
Management Comments
- No specific management commentary provided in this regulatory disclosure.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent, particularly for companies in the clinical development stage.
Comparison to Industry Standards
- The grant size and vesting schedule are consistent with typical compensation packages for directors of mid-cap biotechnology firms.
- The use of stock options as a primary incentive tool aligns with industry norms for incentivizing long-term oversight.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 80,000 stock options to Director David Piacquad. | 2026-05-27 | Standard equity alignment; no material change to governance structure. |
Stakeholder Impact
- Minor potential dilution for existing shareholders upon future exercise of options.
Next Steps
- Vesting of options on May 27, 2027, or the date of the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 2026-05-27 | Date of the stock option grant transaction. |
| 2026-05-29 | Date the Form 4 was filed with the SEC. |
| 2027-05-27 | Vesting date for the stock options (or the date of the next Annual Meeting). |
| 2036-05-26 | Expiration date of the stock options. |
Keywords
Neumora Therapeutics, NMRA, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.